TY - JOUR
T1 - Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice
AU - Lafferty, Ryan
AU - Tanday, Neil
AU - Moffett, Charlotte
AU - Reimann, Frank
AU - Gribble, Fiona
AU - Flatt, PR
AU - Irwin, Nigel
N1 - Funding Information:
The authors would also like to thank Bernard Thorens (University of Lausanne) for his helpful advice on various technical aspects related to the Ins1 Cre/+;Rosa26-eYFP mouse model.
Publisher Copyright:
© Copyright © 2021 Lafferty, Tanday, Moffett, Reimann, Gribble, Flatt and Irwin.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/2/25
Y1 - 2021/2/25
N2 - Enzymatically stable and specific neuropeptide Y1 receptor (NPYR1) agonists, such as sea lamprey PYY(1-36) (SL-PYY(1-36)), are believed to improve glucose regulation in diabetes by targeting pancreatic islets. In this study, streptozotocin (STZ) diabetic transgenic ; and ; mouse models have been used to study effects of sustained NPYR1 activation on islet cell composition and alpha- and beta-cell lineage transitioning. STZ induced a particularly severe form of diabetes in ; mice, but twice-daily administration (25 nmol/kg) of SL-PYY(1-36) for 11 days consistently improved metabolic status. Blood glucose was decreased (p <0.05 - p <0.001) and both fasted plasma and pancreatic insulin significantly increased by SL-PYY(1-36). In both ; and ; mice, STZ provoked characteristic losses (p <0.05 - p <0.001) of islet numbers, beta-cell and pancreatic islet areas together with increases in area and central islet location of alpha-cells. With exception of alpha-cell area, these morphological changes were fully, or partially, returned to non-diabetic control levels by SL-PYY(1-36). Interestingly, STZ apparently triggered decreased (p <0.001) alpha- to beta-cell transition in ; mice, together with increased loss of beta-cell identity in ; mice, but both effects were significantly (p <0.001) reversed by SL-PYY(1-36). SL-PYY(1-36) also apparently reduced (p <0.05) beta- to alpha-cell conversion in ; mice and glucagon expressing alpha-cells in ; mice. These data indicate that islet benefits of prolonged NPY1R activation, and especially restoration of beta-cell mass, are observed irrespective of diabetes status, being linked to cell lineage alterations including transdifferentiation of alpha- to beta-cells. [Abstract copyright: Copyright © 2021 Lafferty, Tanday, Moffett, Reimann, Gribble, Flatt and Irwin.]
AB - Enzymatically stable and specific neuropeptide Y1 receptor (NPYR1) agonists, such as sea lamprey PYY(1-36) (SL-PYY(1-36)), are believed to improve glucose regulation in diabetes by targeting pancreatic islets. In this study, streptozotocin (STZ) diabetic transgenic ; and ; mouse models have been used to study effects of sustained NPYR1 activation on islet cell composition and alpha- and beta-cell lineage transitioning. STZ induced a particularly severe form of diabetes in ; mice, but twice-daily administration (25 nmol/kg) of SL-PYY(1-36) for 11 days consistently improved metabolic status. Blood glucose was decreased (p <0.05 - p <0.001) and both fasted plasma and pancreatic insulin significantly increased by SL-PYY(1-36). In both ; and ; mice, STZ provoked characteristic losses (p <0.05 - p <0.001) of islet numbers, beta-cell and pancreatic islet areas together with increases in area and central islet location of alpha-cells. With exception of alpha-cell area, these morphological changes were fully, or partially, returned to non-diabetic control levels by SL-PYY(1-36). Interestingly, STZ apparently triggered decreased (p <0.001) alpha- to beta-cell transition in ; mice, together with increased loss of beta-cell identity in ; mice, but both effects were significantly (p <0.001) reversed by SL-PYY(1-36). SL-PYY(1-36) also apparently reduced (p <0.05) beta- to alpha-cell conversion in ; mice and glucagon expressing alpha-cells in ; mice. These data indicate that islet benefits of prolonged NPY1R activation, and especially restoration of beta-cell mass, are observed irrespective of diabetes status, being linked to cell lineage alterations including transdifferentiation of alpha- to beta-cells. [Abstract copyright: Copyright © 2021 Lafferty, Tanday, Moffett, Reimann, Gribble, Flatt and Irwin.]
KW - peptide YY
KW - sea lamprey PYY
KW - diabetes
KW - transdifferentiation
KW - streptozotocin
UR - http://www.scopus.com/inward/record.url?scp=85102462508&partnerID=8YFLogxK
U2 - 10.3389/fendo.2021.633625
DO - 10.3389/fendo.2021.633625
M3 - Article
VL - 12
SP - 1
EP - 10
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
SN - 1664-2392
M1 - 633625
ER -